NASDAQ$AHCO

AdaptHealth Corp. · Q4 2024 earnings

Q4 2024 earnings · · Before market open · Investor relations

Briefing

Announced fourth quarter and full-year 2024 results, providing a 2025 outlook.

AdaptHealth reported a slight decrease in net revenue for Q4 2024, but net income increased significantly compared to the previous year. The company is focusing on key initiatives like the One Adapt program and leveraging AI to drive long-term success.

  • Net revenue decreased slightly by 0.2% to $856.6 million compared to Q4 2023.
  • Net income attributable to AdaptHealth Corp. was $50.3 million, a significant improvement from a net loss of $254.5 million in Q4 2023.
  • Adjusted EBITDA decreased by 2.0% to $200.6 million compared to $204.6 million in Q4 2023.
  • Free cash flow increased to $73.1 million from $66.6 million in Q4 2023.

Headline financials

Total Revenue

$857M

Previous: $858M-0.2%
EPS (adj)

$0.34

Previous: $0.49-30.6%
Adjusted EBITDA

$201M

No prior period
Adjusted EBITDA Margin

23.4%

No prior period
Net Income

$51.4M

Previous: -$254M+120.3%
Operating Income

$97.7M

Previous: $101M-3.4%

Revenue & EPS history

AdaptHealth · Revenue · Quarterly

$857M

Q4 2024-0.2%vs Q4 2023
Beat estimate in 7 of 15 quarters(47%)
ActualEstimate

Forward guidance

The Company is providing its financial guidance for fiscal year 2025, as follows: Net revenue of $3.22 billion to $3.36 billion; Adjusted EBITDA of $670 million to $710 million; Free cash flow of $180 million to $220 million

Tailwinds

  • Net revenue of $3.22 billion to $3.36 billion
  • Adjusted EBITDA of $670 million to $710 million
  • Free cash flow of $180 million to $220 million

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+0.6%

Avg return

Earnings day

+1.4%

Avg return

5 days after

+1.6%

Avg return

30 days after

52%

16 / 31 earnings

Positive

+34.6%

Q4 2023

Best reaction

-27.9%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-10.0%-13.4%-25.6%
Q4 2025-14.2%-11.1%+10.9%
Q3 2025+17.2%+4.5%+3.2%
Q1 2025+1.7%-1.4%+3.7%
Q4 2024+24.4%+33.1%+24.4%
Q3 2024+0.3%-0.6%-4.2%
Q2 2024-17.2%-14.1%+4.6%
Q1 2024-8.6%-8.8%+4.9%
Q4 2023+34.6%+37.9%+50.9%
Q3 2023-23.1%-18.6%-5.6%
Q2 2023+11.1%+4.4%-19.8%
Q1 2023-8.4%-12.2%-13.8%
Q4 2022-27.9%-27.9%-40.6%
Q3 2022-1.6%+8.4%+4.5%
Q2 2022-8.9%-8.2%-25.7%
Q1 2022+23.7%+42.2%+53.6%
Q4 2021+4.1%+2.3%+2.8%
Q3 2021-5.4%-7.2%-24.1%
Q2 2021+16.4%+13.4%+12.3%
Q1 2021-8.5%-14.9%-10.4%
Q4 2020+2.1%+12.4%+21.7%
Q3 2020+2.6%+0.6%+19.5%
Q2 2020+13.9%+18.0%+7.0%
Q1 2020+1.6%+5.8%+5.5%
Q4 2019+1.8%+1.4%-7.7%
Q3 2019-4.1%-4.9%-3.3%
Q2 2019+0.0%+0.0%-0.6%
Q1 2019+0.0%+0.0%+0.3%
Q4 2018+0.6%+0.7%+1.3%
Q3 2018+0.3%+0.1%+0.4%
Q2 2018+0.0%+0.3%+0.1%
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro